NYSEAMERICAN:ATNM - Actinium Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.63 -0.04 (-5.97 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$0.67
Today's Range$0.63 - $0.71
52-Week Range$0.33 - $1.33
Volume1.91 million shs
Average Volume1.07 million shs
Market Capitalization$32.44 million
P/E RatioN/A
Dividend YieldN/A
Beta40.64
Actinium Pharmaceuticals logoActinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.

Receive ATNM News and Ratings via Email

Sign-up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:ATNM
CUSIPN/A
Phone+1-646-6773875

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-187.42%
Return on Assets-146.18%

Miscellaneous

EmployeesN/A
Outstanding Shares110,200,000

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Frequently Asked Questions

What is Actinium Pharmaceuticals' stock symbol?

Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM."

How were Actinium Pharmaceuticals' earnings last quarter?

Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) announced its quarterly earnings results on Monday, March, 16th. The biotechnology company reported ($0.17) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.19) by $0.02. View Actinium Pharmaceuticals' Earnings History.

What price target have analysts set for ATNM?

4 brokerages have issued 1-year price objectives for Actinium Pharmaceuticals' stock. Their forecasts range from $3.00 to $6.00. On average, they expect Actinium Pharmaceuticals' share price to reach $4.50 in the next twelve months. View Analyst Ratings for Actinium Pharmaceuticals.

What are Wall Street analysts saying about Actinium Pharmaceuticals stock?

Here are some recent quotes from research analysts about Actinium Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company's principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. " (6/19/2018)
  • 2. Maxim Group analysts commented, "Actinium announced initiation of a Phase 1 study of Actimab-A (Actinium-225 labeled anti CD33 antibody) + salvage chemotherapy (CLAG-M) in relapsed/ refractory acute myeloid leukemia (r/r AML)." (6/14/2018)

Are investors shorting Actinium Pharmaceuticals?

Actinium Pharmaceuticals saw a decrease in short interest in May. As of May 31st, there was short interest totalling 714,939 shares, a decrease of 29.1% from the May 15th total of 1,008,115 shares. Based on an average trading volume of 548,849 shares, the short-interest ratio is presently 1.3 days. Currently, 0.7% of the company's shares are sold short. View Actinium Pharmaceuticals' Current Options Chain.

Who are some of Actinium Pharmaceuticals' key competitors?

Who are Actinium Pharmaceuticals' key executives?

Actinium Pharmaceuticals' management team includes the folowing people:
  • Mr. Sandesh C. Seth, Exec. Chairman and Chief Exec. Officer (Age 54)
  • Mr. Steven O'Loughlin BS, Principal Financial & Accounting Officer and VP of Fin. & Corp. Devel. (Age 32)
  • Dr. Mark S. Berger M.D., Chief Medical Officer (Age 63)
  • Dr. Nitya G. Ray Ph.D., Exec. VP and Head of Product Devel., Manufacturing & Supply Chain (Age 65)
  • Dr. Dale L. Ludwig, Chief Scientific Officer

Has Actinium Pharmaceuticals been receiving favorable news coverage?

News headlines about ATNM stock have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Actinium Pharmaceuticals earned a coverage optimism score of 0.16 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 46.07 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are Actinium Pharmaceuticals' major shareholders?

Actinium Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Anson Funds Management LP (3.73%), Sabby Management LLC (1.81%), Sio Capital Management LLC (0.98%), Worth Venture Partners LLC (0.35%) and Worth Venture Partners LLC (0.35%). Company insiders that own Actinium Pharmaceuticals stock include Ajit Shetty, Nitya G Ray, Sandesh Seth, Sloan-Kettering Cance Memorial and Steve O'loughlin. View Institutional Ownership Trends for Actinium Pharmaceuticals.

Which institutional investors are buying Actinium Pharmaceuticals stock?

ATNM stock was purchased by a variety of institutional investors in the last quarter, including Anson Funds Management LP, Sabby Management LLC, Sio Capital Management LLC, Worth Venture Partners LLC and Worth Venture Partners LLC. Company insiders that have bought Actinium Pharmaceuticals stock in the last two years include Ajit Shetty, Nitya G Ray, Sandesh Seth and Steve O'loughlin. View Insider Buying and Selling for Actinium Pharmaceuticals.

How do I buy shares of Actinium Pharmaceuticals?

Shares of ATNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Actinium Pharmaceuticals' stock price today?

One share of ATNM stock can currently be purchased for approximately $0.63.

How big of a company is Actinium Pharmaceuticals?

Actinium Pharmaceuticals has a market capitalization of $32.44 million.

How can I contact Actinium Pharmaceuticals?

Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The biotechnology company can be reached via phone at +1-646-6773875.


MarketBeat Community Rating for Actinium Pharmaceuticals (ATNM)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  157 (Vote Outperform)
Underperform Votes:  69 (Vote Underperform)
Total Votes:  226
MarketBeat's community ratings are surveys of what our community members think about Actinium Pharmaceuticals and other stocks. Vote "Outperform" if you believe ATNM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATNM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.